Kestra Advisory Services’s Iovance Biotherapeutics IOVA Stock Holding History

Kestra Advisory Services’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$140K	Sell	33,667 -1,224	-4%	-$4.65K	﹤0.01%	3146
2026 Q1	$122K	Buy	34,891 +24,700	+242%	+$79K	﹤0.01%	3009
2025 Q4	$27.8K	Sell	10,191 -2,000	-16%	-$4.63K	﹤0.01%	4333
2025 Q3	$26.5K	Sell	12,191 -21,000	-63%	-$49.6K	﹤0.01%	2875
2025 Q2	$57.1K	Buy	33,191 +16,915	+104%	+$42.1K	﹤0.01%	2765
2025 Q1	$54.2K	Sell	16,276 -30,865	-65%	-$159K	﹤0.01%	2643
2024 Q4	$349K	Buy	47,141 +36,196	+331%	+$336K	﹤0.01%	2126
2024 Q3	$103K	Sell	10,945 -20,830	-66%	-$197K	﹤0.01%	2462
2024 Q2	$101K	Buy	31,775 +2,692	+9%	+$28.8K	﹤0.01%	2520
2024 Q1	$431K	Buy	+29,083	New	+$339K	﹤0.01%	1760

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Kestra Advisory Services's IOVA Position: Q2 2026 in Review

Kestra Advisory Services reduced its Iovance Biotherapeutics (IOVA) stake by 3.5% in Q2 2026, selling an estimated $4.65K and leaving 33,667 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #3146.

Kestra Advisory Services first reported a position in IOVA in Q1 2024 and has held it in 10 quarters since. The position peaked at $431K in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Kestra Advisory Services held 33,667 shares of Iovance Biotherapeutics worth $140K as of Q2 2026.
Kestra Advisory Services sold 1,224 Iovance Biotherapeutics shares in Q2 2026, an estimated $4.65K.
Iovance Biotherapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3146 holding.
Kestra Advisory Services first reported a position in Iovance Biotherapeutics in Q1 2024 and has held it in 10 quarters since.
Kestra Advisory Services's Iovance Biotherapeutics position peaked at $431K in Q1 2024.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.